Author: Kalohexis

Posted Date:

April 17, 2026

Kalohexis Announces Poster Presentation at the American Association for Cancer Research Annual Meeting 2026

Kalohexis

April 17, 2026
Kalohexis Appoints Tony Mitchell as Chief Financial Officer

Kalohexis

March 31, 2026
Kalohexis Announces Publication in Frontiers in Endocrinology Defining Design Criteria for Next-Generation Melanocortin Drugs for General Obesity

Kalohexis

March 25, 2026
Kalohexis Emerges from Stealth to Advance First- and Best-in-Class Therapeutics Harnessing the Melanocortin System to Treat Obesity and Metabolic Diseases

Kalohexis

March 19, 2026